南方科技大学知识苑(SUSTech KC): Tepotinib hydrochloride for the treatment of non-small cell lung cancer

题名	Tepotinib hydrochloride for the treatment of non-small cell lung cancer
作者	Wu，Z. X.1; Li，J.2; Dong，S.3 ; Lin，L.4; Zou，C.3 ; Chen，Z. S.1
发表日期	2021-04-01
DOI	10.1358/dot.2021.57.4.3238323
发表期刊	DRUGS OF TODAY 影响因子和分区
ISSN	1699-3993
卷号	57 期号:4页码:265-275
摘要	Non-small cell lung cancer (NSCLC) is one of the most devastating cancers with high mortality worldwide. By inhibiting the activity of specific molecular targets in the cancer cells, tyrosine kinase inhibitors (TKIs) have become a standard treatment in combating NSCLC. Tepotinib hydrochloride is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations. Tepotinib demonstrated durable clinical response in phase II clinical trials, which led to its approval for use in Japan and breakthrough therapy designation and accelerated approval in the U.S. These progresses highlighted tepotinib as a promising candidate for NSCLC patients. This review summarizes the pharmacological profile of tepotinib, preclinical studies and landmark clinical trials of tepotinib. In addition, we share our perspectives on the future direction of tepotinib as a novel anticancer drug.
关键词	Mesenchymal-epithelial transition (MET) inhibitors Non-small cell lung cancer (NSCLC) Targeted therapy Tepotinib hydrochloride Tyrosine kinase inhibitors
相关链接	[Scopus记录]
收录类别	SCI
语种	英语
学校署名	其他
WOS记录号	WOS:000639023900002
Scopus记录号	2-s2.0-85104287536
来源库	Scopus
引用统计	被引频次[WOS]：3
成果类型	期刊论文
条目标识符	http://sustech.caswiz.com/handle/2SGJ60CL/227757
专题	南方科技大学
作者单位	1.Department of Pharmaceutical Sciences,St. John's University,Queens,College of Pharmacy and Health Sciences,United States 2.Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA and Department of Otolaryngology-Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China 3.Key Laboratory of Medical Electrophysiology of Education Ministry,School of Pharmacy,Southwest Medical University,China and Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis,Southern University of Science and Technology,Shenzhen,China 4.Cell Research Center,Shenzhen Bolun Institute of Biotechnology,Shenzhen,China
推荐引用方式 GB/T 7714	Wu，Z. X.,Li，J.,Dong，S.,et al. Tepotinib hydrochloride for the treatment of non-small cell lung cancer[J]. DRUGS OF TODAY,2021,57(4):265-275.
APA	Wu，Z. X.,Li，J.,Dong，S.,Lin，L.,Zou，C.,&Chen，Z. S..(2021).Tepotinib hydrochloride for the treatment of non-small cell lung cancer.DRUGS OF TODAY,57(4),265-275.
MLA	Wu，Z. X.,et al."Tepotinib hydrochloride for the treatment of non-small cell lung cancer".DRUGS OF TODAY 57.4(2021):265-275.